Skip to content
MedsAcross

Medicine

Aprepitant 125 mg capsule

Aprepitant · Oral
Available on requestPrescription onlyUS FDAGeneric name

Aprepitant 125 mg capsule is a generic prescription medicine for oral use, made by 5 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20 to 25°C (68 to 77°F).

Key facts

Active ingredient (INN)
Aprepitant
Brand
Sold under the generic name
Strength
125 mg
Dosage form
Capsule
Route
Oral
Packs
6 blister pack, 1 blister pack and 3 more
Manufacturers
Torrent PharmaceuticalsIndiaGlenmark PharmaceuticalsIndiaBluePoint LaboratoriesGolden State Medical SupplySandoz
Origin register
US FDA, United States
Storage
Store at 20 to 25°C (68 to 77°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
A04AD12 Fosaprepitant
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
27 December 2016
Identifiers
RxCUI 403810, 403811, 644088 +1DailyMed set ID 377c3ecb-fdec-dde4-e063-6294a90a29bd, a78aaa00-a46b-4f9e-a415-2fca9e9a4fb4, f58b8944-93ee-4be1-a238-cc0061ddd93a +1NDC 51407-703, 13668-748, 68001-668 +3Application ANDA211835, ANDA207777, ANDA090999

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
6 blister pack in 1 carton / 1 capsule in 1 blister pack13668-593-86Torrent PharmaceuticalsIndia21 October 2020
6 blister pack in 1 carton / 1 capsule in 1 blister pack13668-748-86Torrent PharmaceuticalsIndia20 October 2026
1 blister pack in 1 carton / 6 capsule in 1 blister pack68462-585-76Glenmark PharmaceuticalsIndia12 October 2017
1 blister pack in 1 carton / 6 capsule in 1 blister pack0781-2323-68Sandoz27 December 2016
1 blister pack in 1 carton / 6 capsule in 1 blister pack68001-668-19BluePoint Laboratories10 February 2026
6 blister pack in 1 carton / 1 capsule in 1 blister pack51407-703-06Golden State Medical Supply11 June 2025

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 26 March 2003Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Aprepitant 125 mg capsule.

Compare 1

Other strengths and forms of Aprepitant

Clinical summary

Aprepitant is a substance P/neurokinin-1 receptor antagonist. It is available as capsules, injectable emulsion and kits for oral and intravenous use. MedsAcross supplies Aprepitant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Aprepitant

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Aprepitant 125 mg capsule for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.